Objective: The p21-activated kinase serine/threonine kinases have been outlined as the main cytoskeletal remolding regulators. The same holds true for cell proliferation and motility. They additionally have a part in cellular invasion and carcinogenesis, but the effect of p21-activated kinase 1 expression on the progression of upper urinary tract urothelial carcinoma remains unclear. Therefore, we assessed the relation of p21-activated kinase 1 positivity level to clinicopathological features in patients with upper urinary tract urothelial carcinoma. Methods: Immunohistochemical staining was performed using formalin-fixed and paraffin-embedded specimens, which were all from 124 patients with upper urinary tract urothelial carcinoma. The determination of staining level was based on the intensity of the staining along with portion of cells stained. Correlation of p21-activated kinase 1 positivity with clinicopathological parameters, including disease-specific or extravesical-recurrence-free survival, was evaluated. Results: Statistically significant association was observed between moderate or more than moderate p21-activated kinase 1 positivity and higher tumor grade, pathological T stage, lymphovascular invasion, history of adjuvant chemotherapy and extravesical recurrence. Positivity for p21-activated kinase 1 had a significant association with shortened disease-specific survival in a multivariate analysis among clinicopathological parameters. Strongly positive p21-activated kinase 1 expression was also one of the independent factors for shortened extravesical-recurrence-free survival time in N0M0 upper urinary tract urothelial carcinoma patients in another multivariate analysis as well as histology and lymphovascular invasion (P = 0.0304, hazard ratio = 4.425). Conclusions: We conclude that our findings can help us continue a careful follow-up for upper urinary tract urothelial carcinoma patients with high p21-activated kinase 1 expression in surgical specimens.
Introduction
Upper urinary tract (UUT) urothelial carcinomas (UCs) account for <10% of all urothelial carcinomas (1, 2) but are estimated to occur in about two new patients per 100 000 inhabitants annually in Western countries. Tumors in the urinary pelvis, calices or both are about twice as common as ureteral tumors. In 17% of cases, concurrent bladder cancer is present (3) . Intravesical recurrence occurs in 22-47% of UUT-UC patients (2, 4, 5) , whereas recurrence in the contralateral upper tract is observed in just 2-6% (6,7).
Many patients undergoing radical surgery take only a few years to develop systemic metastases, so the projection health for patients with UUT-UC tends to be relatively poor (8) , presumably because of occult micrometastasis penetrating through the thin walls at the time of surgery along with the ureter getting drained of rich lymphatics.
Metastasis, which basically involves the spreading of tumor cells from the main site to a distant one (9) , is one of the primary reasons for people dying of cancer. Different pathological research have tried to outline that recurrence is linked to muscle invasion, improperly distinguished cancer, lymphovascular invasion (LVI) along with lymph node metastasis; these factors additionally lead to weak prognoses in terms of UUT-UC (8, 10, 11) . Therefore, the lymph node metastasis and LVI are utilized in helping develop a prognosis.
Recently, p21-activated kinase (PAK) serine/threonine kinases have been outlined as the main cytoskeletal remolding regulators. The same holds true for cell proliferation and motility. They additionally have a part in cellular invasion and carcinogenesis (12) . PAK1, which is the most appropriately characterized member of this domain, has demonstrated a hike in activity and expression in terms of cancers that afflict humans (12) (13) (14) . Multiple signaling pathways come together to augment the activation of PAK1 via several forms of tyrosine kinases and GTPases (12) . In fact, PAK1 expression is reported to be a helpful marker i.e. it can be used to develop a prognosis for bladder carcinoma which is non-muscle invasive (15) , and its expression is also reported to correlate with LVI and lymph node metastasis of UUT-UC, which is considered a major cause of poor prognosis in patients with this type of cancer, as stated above. Therefore, PAK1 expression level may be a prognostic marker for this disease (16) .
In the present study, we retrospectively analyzed records from our institution and assessed the relation of PAK1 positivity level to clinicopathological features to clarify whether PAK1 expression level in primary tumors predicts disease-specific and/or extravesicalrecurrence-free survival in patients with UUT-UC. Only a handful of reports have examined human UUT-UC tissues in terms of PAK1 expression, and we believe that information pertaining to PAK1 can prove helpful for creating strategies for individual treatment.
Patients and methods

Patients
We retrospectively reviewed and analyzed clinicopathological data from the medical records of 124 UUT-UC patients. The study protocol was approved by our institutional ethics committee. The patients included 30 women and 94 men. The median patient age was 69 (range: 38-86 years) and the mean follow-up period after surgery was 55.6 months (range: 3.5-157.4 months). Table 1 shows additional clinicopathological data. In the present study, extravesical recurrence was considered to have occurred if nodal and/or visceral metastasis was found on radiograph examination (17) .
Laparoscopic nephroureterectomy was performed for 45 patients, open nephroureterectomy was performed for 77 patients, and partial ureterectomy was performed for two patients at our institution between March 1999 and December 2010. The two patients who underwent partial ureterectomy were carefully followed up and are still alive without any local recurrence or distant metastasis. No patients had distant metastasis at diagnosis. Pathological staging was conducted in accordance with the 2002 American Joint Committee on Cancer guidelines.
LVI was assessed at our institution by pathologists, but differentiation of lymphatic vessels from blood vessels was not performed in some specimens, so we recognized positive LVI when lymphatic invasion or vascular invasion, or both, were found. Extended lymphadenectomy was not routinely performed, but lymph nodes around the ipsilateral renal hilum were removed from patients with renal pelvic or upper ureteral cancer, or with both cancers.
No patients received neoadjuvant chemotherapy but 30 received adjuvant chemotherapy. Most of the patients treated with adjuvant chemotherapy had one or more advanced pathological factors such as ≥pT3, positive lymph node metastasis or positive LVI, but the decision for conducting adjuvant chemotherapy was left to the attending urologists and no designated chemotherapy regimens existed at our institution during this period.
Immunohistochemical staining of PAK1 and evaluation
Specimens were collected from the 124 primary UUT-UC patients and paraffin-embedded. We did not perform immunohistochemical staining of PAK1 for any metastatic lesions. Sections (5 µm) were retrieved from the formalin-embedded block of each specimen. Immunohistochemical staining was performed in the same manner as described previously (18) . Briefly, the sections were deparaffinized in xylene and then graded ethanol was used to dehydrate them. After dehydrating them for 30 min the antigen retrieval was conducted at 95°C with Target Retrieval Solution (Dako, Glostrup, Denmark) following which it was allowed to cool for over 40 min at regular room temperature. After this procedure, DAKO Peroxidase Blocking Reagent (Dako) was used to quench the endogenous peroxidase activity for a total of 10 min. Normal goat serum was then utilized to block the slides for another 20 min and incubated with the anti-PAK1 rabbit polyclonal antibody (Cell Signaling Technology, Beverly, MA) at 1:50 dilution overnight at 4°C. After reaction with the primary antibody, Simple Stain Max PO Multi was used to incubate the slides for over 60 min (Nichirei Bioscience, Tokyo, Japan). Visualization was achieved through a 2 min immersion of the slides in diaminobenzidinetetrahydrochloride. Hematoxylin was used to counter-stain the slides, and they were further mounted with glass cover slips.
The intensity of the staining was graded (1: negative/weak; 2: moderate; 3: strong) along with portion of cells stained (1: <10%; 2: 10-50%; 3: 50-100%). The overall index of PAK1 expression was determined on the basis of three variables: strongly positive when both scores were 3, moderately positive when either of the scores were 2 or 3 and negative or weakly positive if otherwise, according to our previous report and other reports (18) (19) (20) . Non-cancerous lesions were used as a negative control. The immunohistochemically stained slides were also evaluated for all fields of view in each slide by two urologists (K.K. and A.H.) who were blinded for patient outcome. We counted >1000 cells per slide and selected the appropriate figures for each staining level.
Statistical analysis
Fisher's exact probability test became the mode through which the link in terms of the positivity of PAK1 staining and the clinicopathological parameters. The effect of PAK1 expression on disease-specific and extravesical-recurrence-free survival was evaluated using KaplanMeier plots and the log-rank test. In addition, the Cox proportional hazard model helped in the examination of independent factors for poor disease-specific and extravesical-recurrence-free survival. The statistical analysis was undertaken through JMP version 10.0 (SAS institute, Cary, NC). P values < 0.05 were considered statistically significant.
Results
PAK1 expression in UUT-UC specimens
In the present study, we classified the tumors into one of two groups: 'PAK1-positive', which means PAK1 positivity was greater than or equal to moderately positive, or 'PAK1-negative', which means PAK1 positivity was weakly positive or negative. The positive group reached or exceeded the staining criterion while the negative group included tumors that stained weakly and/or had limited stained areas. This classification was based on the overall index of the percentage of cells that were stained along with how intense the staining was, as detailed in the 'Patients and methods'. PAK1 immunostaining was observed in the cytoplasm in the UUT-UC specimens, but the staining intensity and area varied from tumor to tumor. Representatives of negatively stained tumors (Fig. 1A) , weakly stained tumors (Fig. 1B) , moderately stained tumors (Fig. 1C) , and strongly stained tumors (Fig. 1D) are shown.
Statistical associations between positivity of PAK1 and clinicopathological parameters Positive PAK1 expression was seen in 54 (43.5%) of the specimens. Statistically significant association was observed between positive PAK1 expression and higher tumor grade (G3; P = 0.0033), advanced T stage ( pT3; P = 0.0102), presence of LVI (P < 0.0001), history of adjuvant chemotherapy (experience of treatment with adjuvant chemotherapy; P = 0.0034), and extravesical recurrence (P = 0.0119) ( Table 2) .
Effect of PAK1 expression on survival of patients with UUT-UC Positivity for PAK1 has a significant association with shortened disease-specific survival. This was observed in every single patient, along with extravesical-recurrence-free survival in N0M0 patients. Significantly shorter disease-specific survival was also associated with histology (UC with SCC; P = 0.0011), higher tumor grade (G3; P = 0.0014), advanced T stage ( pT3; P = 0.0003), regional lymph node involvement (≥N1; P < 0.0001), presence of LVI (P < 0.0001), history of adjuvant chemotherapy (experience of treatment with adjuvant chemotherapy; P = 0.0005) and PAK1 positivity (strongly positive PAK1 expression; P = 0.0101) on univariate analysis. Among these factors, LVI and PAK1 positivity were the only independent factors for shorter disease-specific survival time (P = 0.0159, 0.0373, respectively) ( Table 3) . Kaplan-Meier plotting showed that survival rates were worse in patients with a strong PAK1 expression than in those with PAK1 positivity less than a strong expression (P = 0.0006) ( Fig. 2A) . However, extravesical recurrence was one of the independent factors for shortened disease-specific survival time on multivariate analysis in this Cox proportional hazard model (Table 3) if we include post-operative factors in the present parameters (data not shown). In fact, disease-specific survival time was much shorter in patients with extravesical recurrence than in those without extravesical recurrence (P < 0.0001) (Fig. 2B) . From this finding, we created another Cox proportional hazard model to evaluate independent factors for extravesical-recurrence-free survival in the 117 N0M0 patients. The results of univariate analysis showed that histology (UC with SCC; P = 0.0076), higher tumor grade (G3; P = 0.0429), advanced T stage ( pT3; P = 0.0024), presence of LVI (P = 0.0002) and PAK1 positivity (strongly positive PAK1 expression; P = 0.0093) were factors for shorter extravesical-recurrence-free survival time. Among these factors, strongly positive PAK1 expression was one of the independent factors for shortened extravesical-recurrence-free survival time as well as histology and LVI in the multivariate analysis (P = 0.0304, 0.0198, 0.0085, respectively) ( Table 4) . Another graph of KaplanMeier plots shows that survival time was shorter in N0M0 patients with stronger PAK1 expression than in those with PAK1 positivity less than a strong expression (P = 0.0189) (Fig. 2C) .
Discussion
In this retrospective study, we found that PAK1 expression was correlated with LVI but not with lymph node metastasis in patients with UUT-UC. The number of patients with lymph node metastasis was relatively smaller than that of patients with LVI. We believe this is the reason PAK1 expression was correlated with LVI but not with lymph node metastasis on multivariate analysis in the present study. In addition, a Cox proportional hazard model demonstrated that histology, LVI, and strong PAK1 expression were self-determining forecasters of lower extravesical-recurrence-free survival rates. In other words, our findings suggest that strong positivity of PAK1could be a feasible predictor of poor disease-specific and/or extravesicalrecurrence-free survival rates in patients with UUT-UC. We calculated whether there was a significant significance between the group of weakly or negative PAK1 expression and that of greater than or equal to moderately positive PAK1 expression and found that, while there was a significant difference, it would be more beneficial to show the statistical differences among three groups than just those two. This is why we divided patients into three groups when we made the Kaplan-Meier plots ( Fig. 2A and C) .
Human tumor tissue has been studied in the context of PAK1 expression before. Our findings also fall along the same lines in terms of patients with UUT-UC. Breast cancer tissues and metastatic lymph nodes showed an overexpression of PAK1 (21) . In addition, there is a high likelihood that PAK1 had a part in helping determine the local metastatic and invasive potential of many cancer afflicting humans (12) . In the present study, primary tumors' hiked PAK1 expressions were linked to higher tumor grade, higher tumor state, LVI and extravesical recurrence. We also found a positive correlation between PAK1 expression in the primary tumor tissues and shortened diseasespecific and/or extravesical-recurrence-free survival time.
Moreover, in the context of bladder cancers PAK1 is overexpressed in a significant proportion (15) . In an earlier report, treatment with Bacille Calmette-Guerin (BCG) saw success with many patients who suffered from bladder cancer; however the success rate was not 100%. The main reason for this is because BCG therapy works mostly for patients who are suffering from cancers that contain mutations which activate the BCG uptake pathways. This would include activating Ras mutations, PTEN deletion or activated PAK1 (22) . From the findings of these studies, we speculate that the expression of PAK1 could be feasible to predict prognosis in patients with UUT-UC as shown in those with bladder carcinoma.
Based on the finding that PAK1 influences a variety of cellular functions, the identification of factors that control the level of PAK1 protein and activity is very promising. Recent studies have revealed that the Rho family of GTPases, Cdc42 and Chp, target their downstream effecter protein PAK1 for proteasomal degradation (23) . The serine/threonine protein kinase LKB1, a tumor-suppressor gene that is implicated in the suppression of cell growth and metastasis, suppresses PAK1 by phosphorylation of Thr109 in the PBD (24) . Furthermore, CEP-1347, a synthetic derivative of the ATP antagonist K252a, directly inhibits PAK1 activity and selectively blocks the growth of Ras transformants (25) . In addition to small-molecule inhibitor developments, there was a recent report on de novo computational design-based PAK1 interacting protein that can bind the PAK1 auto-inhibitory domain interaction interface in its active conformation and inhibit activation by Cdc42 (26) . The newly reengineered proteins bind to active PAK1 with micromolar affinities, which is a point of favorable beginning; however, further optimizations are needed to make this approach therapeutically feasible. On the basis of these findings, we conclude that these inhibitors could be applied in the treatment of cancer as a single administration or in combination with the commonly used chemotherapy or radiotherapy. Given that PAK1 is widely expressed in a variety of normal tissues, it is important to identify highly selective PAK1 inhibitors that selectively kill cancer cells without damaging normal cells. We should also take into account the potential drug toxicity of PAK1 inhibitors considering their side effects and the development of acquired resistance to PAK1 inhibitor therapy (27) before using PAK1 inhibitors for the treatment of UUT-UC.
The limitations of this study should be mentioned. First, it was retrospective in nature, but our sample size was as large as that of a recently reported study (16) . Second, our follow-up period (<5 years) might not have been long enough. However, several retrospective studies on UUT-UC patients have shown that the median followup period was shorter than 4 years (28,29), so we believe that our findings do support the speculation already established in UUT-UC patients. Third, we investigated expression levels of PAK1 in tumor tissues using the method of immunohistochemical staining alone. We might have detected a more detailed expression profile of PAK1 if we had utilized other modalities such as the microarray used in another study (15) . Even with the limitations at hand, the results that we have obtained are fairly significant. Clinicians can benefit from the additional information because of the PAK1 positivity in UUT-UC specimens.
In an earlier study, PAK1 expression was reported to correlate with a high risk of intravesical recurrence after transurethral resection in patients with bladder carcinoma. In that study, multivariate analysis showcased the fact that intravesical recurrence was dominantly linked to PAK1 expression (15) . Although multiplicity and pathological stage were also highlighted as potential risk factors, we believe the present study is useful for demonstrating the expression level of PAK1 as a risk factor for worse prognosis in patients with UUT-UC.
Conclusion
It is possible that strong positivity of PAK1 is a prognostic factor for shortened time to extravesical recurrence as well as an independent prognosticator of shortened disease-specific survival time. This finding can help us continue a careful follow-up for UUT-UC patients with high PAK1expression in surgical specimens.
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